Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2021 | MagnetisMM-3: elranatamab for myeloma

Alexander Lesokhin • 19 Apr 2021
IMS 2021
Multiple Myeloma Antibodies Elranatamab
MagnetisMM-3

Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the MagnetisMM-3 trial (NCT04649359), a study investigating whether single-agent elranatamab (PF-06863135) can provide clinical benefit in patients with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody that binds to two antigens, CD3 on T-cells and B-cell maturation antigen (BCMA). By bringing T-cells and cancer cells in close proximity, elranatamab can activate the T-cell killing of myeloma cells. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.

More from Alexander Lesokhin

1:33
The potential role of belantamab mafodotin in multiple myeloma
Alexander Lesokhin • 10 Dec 2022
1:00
Highlights at ASH 2022: the promise of T-cell redirecting therapies in multiple myeloma
Alexander Lesokhin • 10 Dec 2022
3:44
Can diet impact treatment outcomes and progression of patients with multiple myeloma?
Alexander Lesokhin • 10 Dec 2022
2:31
Evaluating the safety of maintenance therapy cessation in MRD negative myeloma patients
Alexander Lesokhin • 10 Dec 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals